A study assessing efficacy of 12 or 24 week ledipasvir/sofosbuvir (LDV/SOF) and 12 week LDV/SOF + RBV in treatment-experienced patients with cirrhotic, genotype 1 Hepatitis C: A study from TRIO Network.
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 14 Mar 2016 New trial record